{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:45:03Z","timestamp":1782755103896,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.therap.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T09:32:50Z","timestamp":1554024770000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Does spontaneous adverse drug reactions\u2019 reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre"],"prefix":"10.1016","volume":"74","author":[{"given":"Carole","family":"Nicol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3717-2784","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2019.01.008_bib0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.therap.2016.02.029","article-title":"French pharmacovigilance: missions, organization and perspectives","volume":"71","author":"Vial","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.01.008_bib0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.therap.2016.02.007","article-title":"Pharmacovigilance implemented by patients: a necessity in the 21st century","volume":"71","author":"Lafond","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.01.008_bib0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","article-title":"Patient-reported safety information: a renaissance of pharmacovigilance?","volume":"39","author":"H\u00e4rmark","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2019.01.003","article-title":"The French Levothyrox\u00ae crisis: we did the best we could but\u2026","author":"Mouly","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2019.01.008_bib0135","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. http:\/\/www.signalement-sante.gouv.fr [Accessed 10 February 2019]."},{"key":"10.1016\/j.therap.2019.01.008_bib0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.therap.2018.03.004","article-title":"Understanding the distrust towards the assessment of medicines. Beyond conflict of interests","volume":"73","author":"Tournay","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.01.008_bib0145","series-title":"Guideline on good pharmacovigilance practices (GVP). Module VI. Management and reporting of adverse reactions to medicinal products","author":"EMA","year":"2004"},{"key":"10.1016\/j.therap.2019.01.008_bib0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.therap.2015.09.002","article-title":"Cyberpharmacovigilance: what is the usefulness of the social networks in pharmacovigilance?","volume":"71","author":"Bagheri","year":"2016","journal-title":"Therapie"},{"issue":"5","key":"10.1016\/j.therap.2019.01.008_bib0155","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40264-017-0630-2","article-title":"Adverse drug reaction reports received through the mobile app. VigiBIP\u00ae: a comparison with classical methods of reporting","volume":"41","author":"Montastruc","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF03261980","article-title":"First French experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals","volume":"35","author":"Durrieu","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/PPA.S75761","article-title":"Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan","volume":"9","author":"Yamamoto","year":"2015","journal-title":"Patient Prefer adherence"},{"key":"10.1016\/j.therap.2019.01.008_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/pds.3687","article-title":"Adverse drug reaction reports of patients and healthcare professionals-differences in reported information","volume":"24","author":"Rolfes","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","article-title":"The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis","volume":"40","author":"Rolfes","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0180","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.therap.2017.04.004","article-title":"Comparative relevance of declaration of side effects by patients and health professionals","volume":"72","author":"Lagneau","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.01.008_bib0185","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40264-016-0463-4","article-title":"Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study","volume":"39","author":"Durrieu","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.therap.2017.04.004","article-title":"Pertinence compar\u00e9e des notifications d\u2019effets ind\u00e9sirables de patients et professionnels de sant\u00e9","volume":"72","author":"Lagneau","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.01.008_bib0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bcp.13159","article-title":"Factors affecting patient reporting of adverse drug reactions: a systematic review","volume":"83","author":"Al Dweik","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.01.008_bib0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40264-017-0534-1","article-title":"Patient reporting in the EU: analysis of EudraVigilance data","volume":"40","author":"Banovac","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0205","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13063-018-2560-4","article-title":"Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial","volume":"19","author":"Defer","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.therap.2019.01.008_bib0210","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40264-018-0648-0","article-title":"Interest in a mobile app for two-way risk communication: a survey study among European healthcare professionals and patients","volume":"41","author":"De Vries","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0215","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40264-018-0679-6","article-title":"Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross-sectional study","volume":"41","author":"Oosterhuis","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2019.01.008_bib0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"Vigigrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:09Z","timestamp":1758567189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0040595719300502"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.01.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does spontaneous adverse drug reactions\u2019 reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}